Search
Close this search box.

FDA to Import Syphilis Drug, Extencilline, From France Amid Shortage – Drugs.com MedNews

Medically reviewed by Carmen Pope, BPharm. Last updated on Jan 11, 2024.

By Robin Foster HealthDay Reporter

THURSDAY, Jan. 11, 2024 — Amid an ongoing shortage of the first-line treatment for syphilis in the United States, the U.S. Food and Drug Administration will allow the importation of a different syphilis drug from a French drugmaker.

In a letter from Laboratoires Delbert, the Paris-based company said it’s working with the FDA to temporarily import 3.5 million units of Extencilline, which is not approved in the United States. The move was approved by the FDA on Wednesday.

Bicillin, a long-acting injectable form of penicillin made by Pfizer that is similar to Extencilline, has been in short supply in the United States since the middle of 2023.

It is the recommended treatment for syphilis in adults and it’s the only recommended treatment for pregnant women to prevent syphilis passing from mother to newborn.

The National Coalition of STD Directors applauded the FDA’s move.

“The delays in treatment that women have faced because of the shortage has placed them and their families at grave risk during the nation’s syphilis crisis,” executive director David Harvey said in a statement. “Today, the administration took meaningful action on our ongoing ask they do anything and everything in their power to address the Bicillin L-A shortage and to provide communities with the resources they need to treat patients and solve this public health crisis.”

“We hope this is the first step toward seeing a resolution to this shortage, and that HHS [U.S. Department of Health and Human Services] and FDA will continue to take steps to ensure that communities never experience a syphilis treatment shortage again,” Harvey added.

In October, the coalition joined dozens of other public health groups in urging the Biden administration to address the Bicillin shortage as syphilis cases jumped across the country, CNN reported. The FDA’s drug shortages database says the supply problem should ease in the second quarter of 2024.

Syphilis cases have jumped about 74% between 2017 and 2021, while cases of syphilis in newborns increased more than 203%, according to data from the U.S. Centers for Disease Control and Prevention.

Syphilis in infants can be severe, disabling and even fatal. A single course of penicillin at least a month before delivery nearly always prevents infected mothers from passing the disease to their babies.

Sources

  • FDA Drug Shortages database, Jan. 10, 2024
  • CNN

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Read this next

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.